State of Michigan Retirement System Grows Stock Holdings in Hims & Hers Health, Inc. $HIMS

State of Michigan Retirement System increased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 49.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,057,700 shares of the company’s stock after purchasing an additional 678,600 shares during the period. Hims & Hers Health makes up 0.6% of State of Michigan Retirement System’s holdings, making the stock its 27th biggest position. State of Michigan Retirement System’s holdings in Hims & Hers Health were worth $116,713,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in Hims & Hers Health by 0.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after purchasing an additional 200 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Hims & Hers Health by 6.1% in the 3rd quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock valued at $232,000 after buying an additional 236 shares during the period. Concurrent Investment Advisors LLC boosted its stake in shares of Hims & Hers Health by 1.8% in the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after buying an additional 252 shares during the last quarter. Bessemer Group Inc. raised its position in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after acquiring an additional 312 shares in the last quarter. Finally, WealthPlan Investment Management LLC lifted its holdings in Hims & Hers Health by 2.6% in the second quarter. WealthPlan Investment Management LLC now owns 16,404 shares of the company’s stock valued at $818,000 after acquiring an additional 410 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of analyst reports. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. KeyCorp initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating on the stock. Leerink Partners raised shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Finally, UBS Group set a $32.00 target price on Hims & Hers Health in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $42.62.

Hims & Hers Health Trading Down 2.0%

Shares of Hims & Hers Health stock opened at $23.02 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. Hims & Hers Health, Inc. has a twelve month low of $21.12 and a twelve month high of $72.98. The firm has a market capitalization of $5.24 billion, a PE ratio of 42.63, a P/E/G ratio of 3.87 and a beta of 2.43. The firm’s 50-day moving average price is $32.96 and its 200 day moving average price is $43.47.

Hims & Hers Health announced that its Board of Directors has initiated a stock repurchase plan on Monday, November 17th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to buy up to 3% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other news, insider Irene Becklund sold 8,411 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $308,767.81. Following the sale, the insider directly owned 2,126 shares of the company’s stock, valued at $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the transaction, the insider directly owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. This represents a 53.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 131,974 shares of company stock valued at $4,763,800. 13.71% of the stock is owned by corporate insiders.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: HIMS is expanding its care stack by adding multicancer screening (Grail’s Galleri) to its platform, which can increase revenue per patient and strengthen its diagnostics-to-care ecosystem. Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
• Positive Sentiment: Analysts note HIMS is scaling a platform-led digital healthcare model (Labs, AI, YourBio Health) that could lift margins and stickiness if execution continues. Hims & Hers Strengthens Platform-Led Digital Healthcare Model
• Neutral Sentiment: Market response has been volatile: initial share gains after the $49 semaglutide reveal were followed by declines as legal and regulatory reactions emerged; expect elevated volume and short-term price swings. Hims’ $49 weight-loss pill rattles investor case for cash-pay obesity market
• Negative Sentiment: Novo Nordisk has publicly accused HIMS of illegal mass compounding and has vowed legal action, creating litigation risk, potential injunctions, and reputation/partnership fallout. Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding’ Over Cheaper Wegovy Version
• Negative Sentiment: The FDA’s leadership signaled potential enforcement against mass-marketed copycat drugs, raising regulatory risk that could limit HIMS’s ability to sell compounded GLP‑1s at scale. FDA’s Makary pledges crackdown on mass marketing of ‘illegal copycat drugs’
• Negative Sentiment: Broader market impact: major pharma peers (Novo, Eli Lilly) saw share moves tied to the story, and investors are weighing potential costly legal fights, regulatory scrutiny, and patient-safety scrutiny that could blunt near-term revenue from the pill initiative. Hims & Hers falls after Novo’s legal threat

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.